FeesSafety
Pluang+

XCharge reports 61% revenue growth and raises 2026 outlook to 32-57% growth

Company Fundamentals
10 Nov 2026, 14:30 WIB
GlobeNewsWire
View Source
Bullish
XCharge reports 61% revenue growth and raises 2026 outlook to 32-57% growth

XCharge, a global EV charging solutions provider, reported a 61% year-over-year revenue increase to $9.1 million in Q3 2026, with deliveries up 46%. The company raised its full-year 2026 revenue forecast to $33.2 million–$39.4 million, reflecting 32% to 57% growth. This growth is driven by strong demand and fulfillment of customer deliveries. XCharge plans to focus on project delivery and financial discipline for the remainder of the year.

XCharge reported a 61% year-over-year revenue growth in Q3 2026, reaching $9.1 million. For readers following the Technology sector, here is Pluang's market snapshot as of Nov 10, 2026 19:03 WIB: out of 150 priced US tech stocks, 45 rose and 99 fell. Notable movers include IONQ at USD 34.25 with a 3.08% decline and 70% sell order activity, Rigetti Computing (RGTI) at USD 12.61 down 2.85% with 74% sell orders, and 8x8 Inc (EGHT) at USD 2.23 up 2.76% but with 100% sell orders. Typical hold times range from 18 to 40 days.

More News

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...

Market News
Neutral
57 minutes ago
Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...

Market News
Bullish
57 minutes ago
PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...

Company Fundamentals
Bullish
57 minutes ago
Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...

Company Fundamentals
Bullish
57 minutes ago
Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App